Login to Your Account



Novartis, Intercell Form Deal Worth Up To €67M

By Cormac Sheridan


Wednesday, June 14, 2006

No Abstract

 

BioWorld International Correspondent

Intercell AG entered a marketing and distribution agreement with Novartis AG under which the latter company will sell its Japanese encephalitis virus (JEV) vaccine, IC51, in the U.S., Europe, Japan, Latin America and other selected territories.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription